CSL LTD

CSL LTD Share · AU000000CSL8 · 890952 (XASX) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CSL LTD
No Price
01.05.2026 17:54
Current Prices from CSL LTD
ExchangeTickerCurrencyLast TradePriceDaily Change
OTC: UTC
UTC
CMXHF
USD
01.05.2026 17:54
89,96 USD
3,12 USD
+3,59 %
XDUS: Düsseldorf
Düsseldorf
CSLLRSL8.DUSB
EUR
30.04.2026 17:30
76,40 EUR
-
XHAM: Hamburg
Hamburg
CSLLRSL8.HAMB
EUR
30.04.2026 15:25
76,01 EUR
-
XDQU: Quotrix
Quotrix
CSLLRSL8.DUSD
EUR
30.04.2026 09:34
76,24 EUR
-
Invested Funds

The following funds have invested in CSL LTD:

Fund
iShares MSCI World Health Care Sector UCITS ETF USD (Dist)
Vol. in million
4.757,12
Percentage (%)
1,30 %
Fund
iShares Refinitiv Inclusion and Diversity UCITS ETF
Vol. in million
373,22
Percentage (%)
0,95 %
Fund
iShares MSCI World ESG Screened UCITS ETF USD (Dist)
Vol. in million
458,01
Percentage (%)
0,18 %
Fund
iShares MSCI World ESG Screened UCITS ETF USD (Acc)
Vol. in million
2.559,48
Percentage (%)
0,18 %
Fund
iShares MSCI World GBP Hedged UCITS ETF (Acc)
Vol. in million
402,13
Percentage (%)
0,17 %
Company Profile for CSL LTD Share
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Company Data

Name CSL LTD
Company CSL Limited
Website https://www.csl.com.au
Primary Exchange XASX ASX
WKN 890952
ISIN AU000000CSL8
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Paul F. McKenzie
Market Capitalization 44 Mrd.
Country Australia
Currency EUR
Employees 32,7 T
Address 45 Poplar Road, 3052 Melbourne
IPO Date 2005-11-18
Dividends from 'CSL LTD'
Ex-Date Dividend per Share
11.03.2026 1,29 USD
10.03.2026 1,30 USD
10.09.2025 1,62 USD
11.03.2025 1,30 USD
10.03.2025 1,31 USD
07.03.2025 1,30 USD
10.09.2024 1,45 USD
09.09.2024 1,47 USD
06.09.2024 1,45 USD
11.03.2024 1,19 USD

Stock Splits

Date Split
19.10.2007 3:1
18.10.2007 3:1

Ticker Symbols

Name Symbol
Over The Counter CMXHF
Düsseldorf CSLLRSL8.DUSB
Frankfurt CSJ.F
Hamburg CSLLRSL8.HAMB
Quotrix CSLLRSL8.DUSD
More Shares
Investors who hold CSL LTD also have the following shares in their portfolio:
ADIDAS AG
ADIDAS AG Share
ALTERYX INC A
ALTERYX INC A Share
BILIBILI INC - AMERICAN DEPOSITARY SHARES
BILIBILI INC - AMERICAN DEPOSITARY SHARES Depository Receipt
DZ BANK CLN E.8628
DZ BANK CLN E.8628 Bond
FIVERR INTERNATIONAL LTD
FIVERR INTERNATIONAL LTD Share
HENKEL AG VZ
HENKEL AG VZ Share
ISV-GOLD.PROD.U.ETF DLA
ISV-GOLD.PROD.U.ETF DLA ETF
JD.CO INC - ADR
JD.CO INC - ADR Depository Receipt
KINROSS GOLD CORP
KINROSS GOLD CORP Share
MÜNCHENER RÜCK AG
MÜNCHENER RÜCK AG Share
NVLIFESTYLE INC
NVLIFESTYLE INC Share
PAYPAL INC
PAYPAL INC Share